Is immuno-oncology shaping the oncology product development landscape?

25 October 2017

Steven Powell, chief executive of UK-based immuno-oncology (I-O) company Macrophage Pharma, gives an overview of developments in this fast-moving space in an Expert View piece.

I-O has dominated the cancer therapy development landscape since the approval of Yervoy (ipilimumab: Bristol-Myers Squibb) in March 2011, followed by the antibody checkpoint inhibitors, Keytruda (pembrolizumab: Merck & Co) in September 2014 and Opdivo (nivolumab: B-MS) in December 2014.

These anti-CTLA-4 and anti-PD-1 checkpoint inhibitors have since been joined by the anti-PD-L1 agents Tecentriq (atezolizumab: Roche/Genentech); Imfinzi (durvalumab: AstraZeneca) and Bavencio (Merck KGaA/Pfizer).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK